Post by Admin on Feb 11, 2019 2:33:48 GMT
Symptomatic therapy in multiple sclerosis- the role of cannabinoids in treating spasticity
Go to:
Abstract
A large proportion of patients with multiple sclerosis (MS) have spasticity, which has a marked impact on their quality of life. Anecdotal evidence suggests a beneficial effect of cannabis on spasticity as well as pain. Recently, randomized, double-blind, placebo-controlled studies have confirmed the clinical efficacy of cannabinoids for the treatment of spasticity in patients with MS. Based on these data, nabiximols (Sativex), a 1:1 mix of Δ-9-tetrahydrocannabinol and cannabidiol extracted from cloned Cannabis sativa chemovars, received approval for treating MS-related spasticity in various countries around the globe. In this article we review the current understanding of cannabinoid biology and the value of cannabinoids as a symptomatic treatment option addressing spasticity in patients with MS.
Keywords: Δ-9-tetrahydrocannabinol, cannabidiol, multiple sclerosis, spasticity, nabiximols
Source: www.ncbi.nlm.nih.gov/pmc/articles/PMC3437528/
Go to:
Abstract
A large proportion of patients with multiple sclerosis (MS) have spasticity, which has a marked impact on their quality of life. Anecdotal evidence suggests a beneficial effect of cannabis on spasticity as well as pain. Recently, randomized, double-blind, placebo-controlled studies have confirmed the clinical efficacy of cannabinoids for the treatment of spasticity in patients with MS. Based on these data, nabiximols (Sativex), a 1:1 mix of Δ-9-tetrahydrocannabinol and cannabidiol extracted from cloned Cannabis sativa chemovars, received approval for treating MS-related spasticity in various countries around the globe. In this article we review the current understanding of cannabinoid biology and the value of cannabinoids as a symptomatic treatment option addressing spasticity in patients with MS.
Keywords: Δ-9-tetrahydrocannabinol, cannabidiol, multiple sclerosis, spasticity, nabiximols
Source: www.ncbi.nlm.nih.gov/pmc/articles/PMC3437528/